The rescheduling of medical cannabis to Schedule III has paradoxically created significant uncertainty for banks serving the ...

Opinion: The rescheduling of medical marijuana could be the start of a broader rescheduling initiative that would affect ...

Cannabis markets await a landmark federal rescheduling hearing as legal proceedings, regulatory developments, and industry ...

Marijuana stocks spiked following the report that the US Drug Enforcement Administration (“DEA”) is reviewing the potential reclassification of cannabis from Schedule I to Schedule III. This ...

Cannabis may be on its way to being less restricted in the U.S. after a recent recommendation from the Health and Human Services Department to reschedule the drug's classification. Last week, the HHS ...

Tilray Brands Inc (NYSE:TLRY) remains in focus within the NYSE Composite Index as cannabis rescheduling discussions influence ...

Louisiana will no longer be part of a lawsuit other states have filed to stop the Trump administration reclassification of ...

A Las Vegas judge declined to dismiss a lawsuit on Wednesday that aims to stop the state from classifying cannabis as a tightly regulated Schedule I drug. The American Civil Liberties Union of Nevada ...

Cannabis stocks rallied on Monday after a report by The Wall Street Journal that President Donald Trump may consider lowering the federal classification of cannabis to a less-dangerous level. The ...